Neoprobe is establishingan Israeli subsidiary to run a radiolabeling facility for monoclonalantibody agents used in its nuclear probe technology (see above).The U.S. firm signed a memorandum of understanding with the Israelifirm Rotem Industries in
Neoprobe is establishingan Israeli subsidiary to run a radiolabeling facility for monoclonalantibody agents used in its nuclear probe technology (see above).The U.S. firm signed a memorandum of understanding with the Israelifirm Rotem Industries in January. Neoprobe will own 95% of Neoprobe-Israeland Rotem the rest.
Located near Temed, Neoprobe-Israel will produce radiolabeledantibodies for use with its RIGS technology in Europe and Israel.The company will also serve as a secondary source of supply forRIGS agents, in addition to Nordion of Canada. Neoprobe has signeda long-term supply agreement with Nordion.
The move is a logical follow-up to its acquisition of MonoCarbAB of Sweden last December, said Neoprobe president David Bupp.
"Neoprobe now has complete control of all aspects of manufacturingand distributing RIGS surgical system targeting agents,"he said.
The agreement with Rotem is contingent on the government ofIsrael providing $3 million in guarantees to help fund the facilityand clinical testing of agents developed there.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.